Proteomics of bone and soft tissue sarcomas

Current Proteomics

Volumn 9, Issue 2, 2012, Pages 94-102

  Dundas, Sinclair R ^a   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Biomarkers; Bone sarcoma; Molecular diagnosis; Proteomics; Soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CRYSTALLINE AB; EZRIN; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHONDROSARCOMA; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; LIPOSARCOMA; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; TUMOR CLASSIFICATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 84862620838     PISSN: 15701646     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016412800786202     Document Type: Review

References (73)

1. Fletcher, C.D.M.; Mertens, F. and Unni, K.K. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002.
2. Weitz, J.; Antonescu, C.R. and Brennan, M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol., 2003, 21, 2719-2725.
3. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet, 1997, 350, 1647-1654.
4. Clark, M. A.; Fisher, C.; Judson I. and Thomas J.M. Soft tissue sarcomas in adults. N. Engl. J. Med., 2005, 353, 701-711.
5. Singer, S.; Demetri, G.D.; Baldin, E.H. and Fletcher C.D. M. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol., 2000, 1, 75-85.
6. Argon, A.; Basaran, M.; Yaman, F.; Dizdar, Y.; Sakar, B.; Camlica, H.; Bavbek, S.E.; Ozger H.; Darendeliler, E. and Onat, H. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. Jpn. J. Clin. Oncol., 2004, 34, 667-672.
7. Kattan, M.W.; Leung, D.H. and Brennan, M.F. Postoperative nomogram for 12-year sarcoma-specific death. J. Clin. Oncol., 2002, 20, 791-796.
8. Borden, E.C.; Baker, L.H.; Bell, R.S.; Bramwell, V.; Demetri, G.D.; Eisenberg, B.L.; Fletcher, C.D.; Fletcher, J.A.; Ladanyi, M.; Meltzer, P.; O'Sullivan, B.; Parkinson, D.R.; Pisters, P.W.; Saxman, S.; Singer, S.; Sundaram, M.; van Oosterom, A.T.; Verweij, J.; Waalen, J.; Weiss, S.W. and Brennan, M.F. Soft tissue sarcomas of adults: state of the translational science. Clin. Cancer Res., 2003, 6, 1941-1956.
9. Weitz, J.; Antonescu, C.R. and Brennan, M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol., 2003, 21, 2719-2725.
10. Antonescu, C.R. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod. Pathol., 2008, 21, S2, S31-S36.
11. Nielsen, T.O.; West, R.B.; Linn, S.C.; Alter, O.; Knowling, M.A.; O'Connell, J.X.; Zhu, S.; Fero, M.; Sherlock, G.; Pollack, J.R.; Brown, P.O.; Botstein, D. and van de Rijn, M. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet, 2002, 359, 1301-1307.
12. Lee, Y.F.; John, M.; Edwards, S.; Clark, J.; Flohr, P.; Maillard, K.; Edema, M.; Baker, L.; Mangham, D.C.; Grimer, R.; Wooster, R.; Thomas, J.M.; Fisher, C.; Judson, I. and Cooper, C.S. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br. J. Cancer, 2003, 88, 510-515.
13. Baird, K.; Davis, S.; Antonescu, C.R.; Harper, U.L.; Walker, R.L.; Chen, Y.; Glatfelter, A.A.; Duray, P.H. and Meltzer, P.S. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res., 2005, 65, 9226-9235.
14. Scapolan, M.; Perin, T.; Wassermann, B.; Canzonieri, V.; Colombatti, A.; Italia, F. and Spessotto, P. Expression profiles in malignant fibrous histiocytomas: clues for differentiating 'spindle cell' and 'pleomorphic' subtypes. Eur. J. Cancer, 2008, 44, 298-309.
15. Boeuf, S.; Kunz, P.; Hennig, T.; Lehner, B.; Hogendoorn, P.; Bovée, J. and Richter, W. A. Chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. J. Pathol., 2008, 216, 158-166.
16. Davicioni, E.; Wai, D.H. and Anderson, M.J. Diagnostic and prognostic sarcoma signatures. Mol. Diagn. Ther., 2008, 12, 359-374.
17. Laé, M.; Ahn, E.H.; Mercado, G.E.; Chuai, S.; Edgar, M.; Pawel, B.R.; Olshen, A.; Barr, F.G. and Ladanyi M. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAXFKHR fusion-negative embryonal rhabdomyosarcomas. J. Pathol., 2007, 212, 143-151.
18. Nakayama, R.; Nemoto, T.; Takahashi, H.; Ohta, T.; Kawai, A.; Seki, K.; Yoshida, T.; Toyama, Y.; Ichikawa, H. and Hasegawa T. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod. Pathol., 2007, 20, 749-759.
19. Subramanian, S.; West, R.B.; Marinelli, R.J.; Nielsen, T.O.; Rubin, B.P.; Goldblum, J.R.; Patel, R.M.; Zhu, S.; Montgomery, K.; Ng, T.L.; Corless, C.L.; Heinrich, M.C. and van de Rijn, M. The gene expression profile of extraskeletal myxoid chondrosarcoma. J. Pathol., 2005, 206, 433-444.
20. Hallor, K.H.; Sciot, R.; Staaf, J.; Heidenblad, M.; Rydholm, A.; Bauer, H.C.; Aström, K.; Domanski, H.A.; Meis, J.M.; Kindblom, L.G.; Panagopoulos, I.; Mandahl, N. and Mertens, F. Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J. Pathol., 2009, 217, 716-727.
21. Beck, A.H.; West, R.B. and van de Rijn, M. Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch., 2010, 456, 141-151.
22. Yanagisawa, K.; Shyr, Y.; Xu, B.J.; Massion, P.P.; Larsen, P.H.; White, B.C.; Roberts, J.R.; Edgerton, M.; Gonzalez, A.; Nadaf, S.; Moore, J.H.; Caprioli, R.M. and Carbone, D.P. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet, 2003, 362, 433-439.
23. Seike, M.; Kondo, T.; Fujii, K.; Okano, T.; Yamada, T.; Matsuno, Y.; Gemma, A.; Kudoh, S. and Hirohashi, S. Proteomic signatures for histological types of lung cancer. Proteomics, 2005, 5, 2939 2948.
24. Dundas, S.R.; Lawrie, L.C.; Rooney, P.H. and Murray, G.I. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J. Pathol., 2005, 205, 74-81.
25. Carpenter, B.; McKay, M.; Dundas, S.R.; Lawrie, L.C.; Telfer, C. and Murray, G.I. Heterogeneous nuclear ribonucleoprotein K is overexpressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br. J. Cancer, 2006, 95, 921-927.
26. Lawrie, L.C.; Fothergill, J.E. and Murray, G.I. Spot the differences: Proteomics in cancer research. Lancet Oncol., 2001, 2, 270-277.
27. Mussunoor, S. and Murray, G.I. The role of annexins in tumour development and progression. J. Pathol., 2008, 216, 131-140.
28. Lawrie, L.; Curran, S.; McLeod, H.L.; Fothergill, J.E. and Murray, G.I. Application of laser capture microdissection and proteomics in colon cancer. Mol. Pathol., 2001, 54, 253-258.
29. Duncan, R.; Carpenter, B.; Main, L.C.; Telfer, C. and Murray, G.I. Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer, 2008, 98, 426-433.
30. O'Dwyer, D.; Ralton, L.D.; O'Shea, A. and Murray, G.I. The proteomics of colorectal cancer: Identification of a protein signature associated with prognosis. PLos One, 2011, 6, e27718.
31. Ma, Y.; Ding, Z.; Qian, Y.; Shi, X.; Castranova, V.; Harner, E.J. and Guo, L. Predicting cancer drug response by proteomic profiling. Clin. Cancer Res., 2006, 12, 4583-4589.
32. Reyzer, M.L.; Caldwell, R.L.; Dugger, T.C.; Forbes, J.T.; Ritter, C.A.; Guix, M.; Arteaga, C.L. and Caprioli, R.M. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res., 2004, 64, 9093-9100.
33. Chaurand, P.; Sanders, M.E.; Jensen, R.A. and Caprioli, R.M. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am. J. Pathol., 2004, 165, 1057-1068.
34. Jensen, O.N. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr. Opin. Chem. Biol., 2004, 8, 33-41.
35. Li, Y.; Dang, T.A.; Shen, J.; Perlaky, L.; Hicks, J.; Murray, J.; Meyer, W.; Chintagumpala, M.; Lau, C.C. and Man, T.K. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics, 2006, 6, 3426-3435.
36. Groseclose, M.R.; Massion, P.P.; Chaurand, P. and Caprioli, R.M. High-throughput proteomic analysis of formalin-fixed paraffinembedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics, 2008, 8, 3715-3724.
37. Balgley, B.M.; Guo, T.; Zhao, K.; Fang, X.; Tavassoli, F.A and Lee, C.S. Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues. J. Proteome Res., 2009, 8, 917-925.
38. Shi, S.R.; Liu, C.; Balgley, B.M.; Lee, C. and Taylor, C.R. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J. Histochem. Cytochem., 2006, 54, 739-743.
39. Peptide atlas is a multi organism, www.peptideatlas.org
40. Proteomics Identifications database (PRIDE), www.ebi.ac.uk/pride
41. Human Proteinpedia, www.humanproteinpedia.org
42. Yanagisawa, K.; Shyr, Y.; Xu, B.J.; Massion, P.P.; Larsen, P.H.; White, B.C.; Roberts, J.R.; Edgerton, M.; Gonzalez, A.; Nadaf, S.; Moore, J.H.; Caprioli, R.M.; Carbone. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet, 2003, 362, 433-439.
43. McLerran, D.; Grizzle, W.E.; Feng, Z.; Bigbee, W.L.; Banez, L.L.; Cazares, L.H.; Chan, D.W.; Diaz, J.; Izbicka, E.; Kagan, J.; Malehorn, D.E.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.; Rosenzweig, N.; Srivastava, S.; Srivastava, S.; Thompson, I.M.; Thornquist, M.; Troyer, D.; Yasui, Y.; Zhang, Z.; Zhu, L. and Semmes, O.J. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem., 2008, 54, 44-52.
44. Kang, J.H.; Park, K.K.; Lee, I.S.; Magae, J.; Ando, K.; Kim, C.H. and Chang, Y.C. Proteome analysis of responses to ascochlorin in a human osteosarcoma cell line by 2-D gel electrophoresis and MALDI-TOF MS. J. Proteome Res., 2006, 5, 2620-2631.
45. Annunen-Rasila, J.; Ohlmeier, S.; Tuokko, H.; Veijola, J. and Majamaa, K. Proteome and cytoskeleton responses in osteosarcoma cells with reduced OXPHOS activity. Proteomics, 2007, 7, 2189-2200.
46. Dimas, K.; Tsimplouli, C.; Anagnostopoulos, A.K.; Mahaira, L.; Iliopoulou, E.; Perez, S.; Vougas, K. and Tsangaris, G.T. The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma). Cancer Genomics Proteom., 2008, 5, 175-237.
47. Suehara, Y.; Kondo, T.; Fujii, K.; Hasegawa, T.; Kawai, A.; Seki, K.; Beppu, Y.; Nishimura, T.; Kurosawa, H. and Hirohashi, S. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics, 2006, 6, 4402-4409.
48. Kawai, A.; Kondo, T.; Suehara, Y.; Kikuta, K. and Hirohashi, S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin. Orthop. Relat. Res., 2008, 466, 2099-2106.
49. Folio, C.; Mora, M.I.; Zalacain, M.; Corrales, F.J.; Segura, V.; Sierrasesúmaga, L.; Toledo, G.; San-Julián, M. and Patiño-García, A. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. J. Proteome Res., 2009, 8, 3882-3888.
50. Holt, G.E.; Schwartz, H.S. and Caldwell, R. Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin. Orthop. Relat. Res., 2006, 450, 105-110.
51. Nagayama, S.; Katagiri, T.; Tsunoda, T.; Hosaka, T.; Nakashima, Y.; Araki, N.; Kusuzak, K.; Nakayama, T.; Tsuboyama, T.; Nakamura, T.; Imamura, M.; Nakamura, Y. and Toguchida, J. Genome- wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res., 2002, 62, 5859-5866.
52. Kamradt, M.C.; Lu, M.; Werner, M.E.; Kwan, T.; Chen, F.; Strohecker, A.; Oshita, S.; Wilkinson, J.C.; Yu, C.; Oliver, P.G.; Duckett, C.S.; Buchsbaum, D.J.; LoBuglio, A.F.; Jordan, V.C. and Cryns, V.L. The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J. Biol. Chem., 2005, 280, 11059-11066.
53. Hotta, T.; Suzuki, H.; Nagai, S.; Yamamoto, K.; Imakiire, A.; Takada, E.; Itoh, M. and Mizuguchi, J. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis- inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J. Orthop. Res., 2003, 21, 949-957.
54. Niforou, K.M.; Anagnostopoulos, A.K.; Vougas, K.; Kittas, C.; Gorgoulis, V.G. and Tsangaris, G.T. The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics, 2008, 5, 63-78.
55. Spreafico, A.; Frediani, B.; Capperucci, C.; Chellini, F.; Paffetti, A.; D'Ambrosio, C.; Bernardini, G.; Mini, R.; Collodel, G.; Scaloni, A.; Marcolongo, R. and Santucci, A. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics, 2006, 6, 3520-3532.
56. Liu, X.; Zeng, B.; Ma, J. and Wan, C. Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest., 2009, 27, 345-352.
57. Guo, Q.C.; Shen, J.N.; Jin, S.; Wang, J.; Huang, G.; Zhang, L.J.; Huang, G.; Yin, J.Q.; Zou, C.Y. and Li, M.T. Comparative proteomic analysis of human osteosarcoma and SV40-immortalized normal osteoblastic cell lines. Acta. Pharmacol. Sin., 2007, 28, 850-858.
58. Bacci, G.; Ferrari, S.; Bertoni, F.; Rimondini, S.; Longhi, A.; Bacchini, P.; Forni, C.; Manfrini, M.; Donati, D. and Picci, P. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J. Clin. Oncol., 2000, 18, 4-11.
59. Argon, A.; Basaran, M.; Yaman, F.; Dizdar, Y.; Sakar, B.; Camlica, H.; Bavbek, S.E.; Ozger, H.; Darendeliler, E. and Onat, H. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. Jpn. J. Clin. Oncol., 2004, 34, 667-72.
60. Kikuta, K.; Tochigi, N.; Shimoda, T.; Yabe, H.; Morioka, H.; Toyama, Y.; Hosono, A.; Beppu, Y.; Kawai, A.; Hirohashi, S. and Kondo, T. Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin. Cancer Res., 2009, 15, 2885-2894.
61. Grisendi, S.; Mecucci, C.; Falini, B. and Pandolfi P.P. Nucleophosmin and cancer. Nat. Rev. Cancer, 2006, 6, 493-505.
62. Petricoin, E.F. III.; Espina, V.; Araujo, R.P.; Midura, B.; Yeung, C.; Wan, X.; Eichler, G.S.; Johann, D.J. Jr.; Qualman, S.; Tsokos, M.; Krishnan, K.; Helman, L.J. and Liotta, L.A. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res., 2007, 67, 3431-3440.
63. Meric-Bernstam, F. and Gonzalez-Angulo, A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol., 2009, 27, 2278-2287.
64. Zou, C.Y.; Smith, K.D.; Zhu, Q.S.; Liu, J.; McCutcheon, I.E.; Slopis, J.M.; Meric-Bernstam, F.; Peng, Z.; Bornmann, W.G.; Mills, G.B.; Lazar, A.J.; Pollock, R.E. and Lev, D. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol. Cancer Ther., 2009, 8, 1157-1168.
65. Davicioni, E.; Anderson, M.J.; Finckenstein, F.G.; Lynch, J.C.; Qualman, S.J.; Shimada, H.; Schofield, D.E.; Buckley, J.D.; Meyer, W.H.; Sorensen, P.H. and Triche, T.J. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol., 2009, 174, 550-564.
66. Singer S.; Socci N.D.; Ambrosini G.; Sambol E.; Decarolis P.; Wu Y.; O'Connor R.; Maki R.; Viale A.; Sander C.; Schwartz G.K. and Antonescu C.R. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res., 2007, 67, 6626-6636.
67. Fritz, B.; Schubert, F.; Wrobel, G.; Schwaenen, C.; Wessendorf, S.; Nessling, M.; Korz, C.; Rieker, R.J.; Montgomery, K.; Kucherlapati, R.; Mechtersheimer, G.; Eils, R.; Joos, S. and Lichter, P. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res., 2002, 62, 2993-2998.
68. Chung, L.; Lau, S.K.; Jiang, Z.; Loera, S.; Bedel, V.; Ji, J.; Weiss, L.M. and Chu, P.G. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma. Am. J. Surg. Pathol., 2009, 33, 1594-1600.
69. Suehara, Y.; Kondo, T.; Seki, K.; Shibata, T.; Fujii, K.; Gotoh, M.; Hasegawa, T.; Shimada, Y.; Sasako, M.; Shimoda, T.; Kurosawa, H.; Beppu, Y.; Kawai, A. and Hirohashi, S. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin. Cancer Res., 2008, 14, 1707-1717.
70. Kang, H.J.; Koh, K.H.; Yang, E.; You, K.T.; Kim, H.J.; Paik, Y.K. and Kim, H. Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics, 2006, 4, 1151-1157.
71. He J.; Whelan S.A.; Lu M.; Shen D.; Chung D.U.; Saxton R.E.; Faull K.F.; Whitelegge J.P. and Chang H.R. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. Int. J. Proteomics, 2011, 2011, 896476.
72. Yocum A.K.; Busch C.M.; Felix C.A. and Blair I.A. Proteomics-based strategy to identify biomarkers and pharmacological targets in leukemias with t(4;11) translocations. J. Proteome Res., 2006, 5, 2743-2753.
73. Ralton, L.D. and Murray, G.I. The use of formalin fixed paraffin embedded tissue for proteomic analysis. J. Clin. Pathol., 2011, 64, 297-302.